钙调神经磷酸酶抑制剂治疗儿童激素抵抗型肾病综合征的疗效
该研究纳入278例接受一线CNI治疗的SRNS患儿,采用竞争风险分析等方法评估缓解与肾衰竭发生率。结果显示非遗传性SRNS在6个月内蛋白尿减少84%,遗传性SRNS减少58%但9-12个月后反弹至治疗前水平;完全缓解率非遗传性42%、遗传性10%;非遗传性CNI应答者15年肾脏生存率92% vs 42%。
要点
- 非遗传性SRNS患儿CNI治疗6个月内蛋白尿减少84%,遗传性减少58%但9-12个月反弹。
- 完全缓解率非遗传性42%、遗传性10%,持续缓解分别仅24%和3%。
- 非遗传性CNI应答者15年肾脏生存率92% vs 42%,独立于突破性蛋白尿。
核心结论
- CNI治疗对非遗传性SRNS患儿可显著减少蛋白尿并改善长期肾脏生存,但遗传性SRNS疗效有限且易反弹。
研究设计与样本
- 纳入278例接受一线CNI治疗的SRNS患儿,采用竞争风险分析估计累积缓解和肾衰竭发生率,Kaplan-Meier和Cox回归分析肾脏生存及CNI应答预测因素,多变量线性混合效应模型评估CNI剂量和谷浓度对蛋白尿的影响。
主要发现
- 6个月内蛋白尿在219例非遗传性SRNS中减少84%(IQR 80%-87%),在59例遗传性SRNS中减少58%(42%-70%),但后者9-12个月内反弹至治疗前水平。
- 完全缓解见于91/219例非遗传性SRNS(42%)和6/59例遗传性SRNS(10%),持续缓解仅53例非遗传性(24%)和2例遗传性(3%)。
- 蛋白尿减少而非完全缓解与使用较高CNI剂量相关。
- 非遗传性SRNS中,CNI治疗期间突破性蛋白尿的12个月和24个月累积风险分别为51%(40%-62%)和65%(54%-75%)。
- 完全缓解患者停药后12个月和24个月复发风险分别为40%(22%-59%)和50%(30%-69%)。
临床怎么用
- 对非遗传性SRNS患儿,CNI是一线有效选择,需关注较高剂量以促进蛋白尿减少,并监测突破性蛋白尿和停药后复发。
- 对遗传性SRNS患儿,CNI疗效有限且易反弹,应谨慎评估获益并考虑替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We aimed to provide evidence for the efficacy of calcineurin inhibitor (CNI) treatment in children with steroid-resistant nephrotic syndrome (SRNS). METHODS: In 278 SRNS children receiving first-line CNI treatment, cumulative remission and kidney failure incidence were estimated using competing risk analysis. Kaplan-Meier and Cox regression analyses were performed to analyze kidney survival, identify predictors of CNI responsiveness and estimate the cumulative incidence of breakthrough proteinuria episodes on or off CNI treatment. The impact of CNI dosage and trough levels on proteinuria was assessed using multivariable linear-mixed effects modeling. RESULTS: Within 6 months of CNI administration, proteinuria was reduced by 84% (interquartile range: 80%-87%) in 219 nongenetic SRNS cases and by 58% (42%-70%) in 59 genetic SRNS cases but returned to pretreatment level in the latter group within 9 to 12 months. Whereas complete remission was observed in 91 of 219 nongenetic SRNS cases (42%) and 6 of 59 genetic SRNS cases (10%), remission was sustained in 53 nongenetic (24%) and 2 genetic (3%) cases only. Proteinuria reduction, but not attainment of complete remission, was associated with the use of higher CNI doses. The cumulative risk of breakthrough proteinuria on CNI treatment was 51% (40%-62%) and 65% (54%-75%) after 12 and 24 months, respectively, in nongenetic SRNS. The postdiscontinuation relapse risk in patients with complete remission was 40% (22%-59%) and 50% (30%-69%) after 12 and 24 months, respectively. Kidney survival in nongenetic SRNS was superior in CNI-responsive children (92% vs. 42% at 15 years), independent of breakthrough proteinuria episodes. CONCLUSION: Our study provides real-world evidence regarding the extent, dynamics, dose-response relationship, and long-term functional impact of CNI therapy in nongenetic and genetic forms of SRNS.
引用
- Trautmann A, Hofstetter J, Lipska-Ziętkiewicz B, et al. Efficacy of Calcineurin Inhibition in Children With Steroid-Resistant Nephrotic Syndrome. Kidney Int Rep. 2025. PMID: 41141535. doi:10.1016/j.ekir.2025.07.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。